Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Long-term Debt
Borrowings due after more than one year.
Aktis Oncology, Inc.NASDAQ: AKTS
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt of $0 in Q1 FY2026
Q1 FY2026 long-term debt was $0.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 long-term debt of $0 is the 5th highest of the 6 companies compared; the peer median is $13.72M.
- Long-term debt amounts to 0.0% of total assets for AKTS, versus a peer median of 10.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $393.66M | +0.5% | +101.8% | 36.7% | |
| Mar 2026 | $31.3M | — | — | 14.4% | |
| Mar 2026 | $13.72M | — | — | 10.0% | |
| Sep 2026 | $10.26M | +155.6% | — | 2.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AKTS) | $13.72M | +78.1% | +101.8% | 10.0% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.